Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.71 | — | — | — | 1.91 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.42 | 128.48 | 101.91 | 78.16 | 1.10 | 62.44 | 123.74 | 5.04 | 27.32 | 10.91 | 1.82 | 1.63 | 9.58 |
| — | +105.8% | -17.6% | +1450.6% | -96.0% | +472.3% | +6697.0% | +208.4% | +185.0% | +33.6% | -77.6% | -80.3% | -81.5% | |
| P/B Ratio | 0.47 | 1.10 | 0.97 | — | 0.80 | 3.02 | 2.63 | 2.02 | 10.43 | 6.11 | 5.41 | 4.48 | 8.28 |
| — | -63.4% | -63.1% | — | -92.3% | -50.6% | -51.4% | -54.9% | +26.0% | +89.3% | — | -90.6% | -90.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | -0.50 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Silence Therapeutics plc's operating margin was -16505.7% in Q3 2025, down 5807.9 pp QoQ and down 14532.2 pp YoY. The trailing four-quarter average of -11805.6% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 141.8% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.7% | 59.7% | 62.1% | 62.0% | 93.4% | -142.9% | -341.1% | 82.2% | 35.9% | 42.6% | 68.9% | 60.1% | 19.0% |
| — | +141.8% | +118.2% | -24.6% | +160.3% | -435.7% | -595.1% | +36.6% | +88.7% | +46.9% | +94.4% | -0.2% | -52.7% | |
| Operating Margin | -146.4% | -16505.7% | -10697.8% | -20006.3% | -12.7% | -1973.5% | -3064.0% | -35.5% | -633.6% | -453.9% | -125.8% | -106.8% | -230.0% |
| — | -736.4% | -249.1% | -56176.6% | +98.0% | -334.8% | -2334.8% | +66.7% | -175.4% | -12.3% | +67.5% | +38.4% | +30.3% | |
| Net Margin | -104.7% | -13181.1% | -12211.6% | -20091.5% | 58.3% | -2365.3% | -2602.3% | -14.7% | -686.6% | -294.9% | -114.2% | -89.7% | -288.8% |
| — | -457.3% | -369.3% | -136325.7% | +108.5% | -702.2% | -2177.8% | +83.6% | -137.7% | -39.9% | +65.1% | +33.2% | -4.5% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -58.1% | -24.9% | -29.1% | -268.1% | 12.4% | -26.1% | -11.6% | -2.6% | -68.6% | -51.2% | -72.1% | -52.8% | -49.0% |
| — | +4.5% | -151.0% | -10246.1% | +118.1% | +49.0% | +84.0% | +95.1% | -40.2% | -5.8% | — | +57.0% | +35.4% | |
| ROA | -28.1% | -13.4% | -15.6% | -14.7% | 7.6% | -15.1% | -7.2% | -1.3% | -13.3% | -8.7% | -11.1% | -10.1% | -11.9% |
| — | +11.0% | -117.6% | -1060.5% | +157.5% | -74.4% | +35.5% | +87.5% | -11.5% | -26.4% | +20.7% | -20.4% | -19.1% | |
| ROIC | -370.7% | -88.2% | -34.3% | — | -10.1% | -94.1% | -159.3% | -29.8% | — | — | — | — | — |
| — | +6.3% | +78.5% | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 17.4% YoY to 7.69x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 |
| — | +67.0% | — | — | -94.5% | -90.7% | -94.5% | -90.7% | -22.1% | +7.7% | — | +6.4% | +25.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.14 | 7.69 | 10.06 | 8.81 | 11.14 | 9.31 | 9.83 | 12.82 | 4.62 | 4.86 | 4.21 | 4.71 | 4.41 |
| — | -17.4% | +2.3% | -31.2% | +141.2% | +91.5% | +133.6% | +172.1% | +4.8% | +11.1% | +12.1% | -3.7% | -22.6% | |
| Quick Ratio | 11.14 | 7.69 | 10.06 | 8.81 | 11.14 | 9.31 | 9.83 | 12.82 | 4.62 | 4.86 | 4.21 | 4.71 | 4.41 |
| — | -17.4% | +2.3% | -31.2% | +141.2% | +91.5% | +133.6% | +172.1% | +4.8% | +11.1% | +12.1% | -3.7% | -22.6% | |
| Interest Coverage | — | — | — | — | — | -2.62 | -100.13 | -429.31 | -14.33 | -1587.38 | -12.83 | -14.13 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonSilence Therapeutics plc's current P/E is -1.7x. The average P/E over the last 1 quarters is 1.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Silence Therapeutics plc's current operating margin is -146.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Silence Therapeutics plc's business trajectory between earnings reports.